20 completed, 8 recruiting, 4 not yet recruiting, 4 terminated. 41 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 20, Recruiting 8, Not yet recruiting 4, Terminated 4, Unknown 4, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo - Mohs Micrographic Surgery, Excision Margin | Phase 2 | Not yet recruiting | University of California, Davis | 220 | 2026-10-01 | 2026-08-18 |
| CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA) - HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2026-09-04 | 2026-10-29 |
| Evaluation of NWRD09 for HPV-16 Related Cervical HSIL NWRD09 Injection, NWRD09 Placebo - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Not yet recruiting | Newish Biotech (Wuxi) Co., Ltd. | 156 | 2026-08-01 | 2026-07-17 |
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination - Cervical Intraepithelial Neoplasia, Papillomavirus Infections | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 230 | 2026-07-01 | 2026-07-09 |
| Defining the Ablative Dose for Y-90 TARE Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Northwestern University | 30 | 2026-05-15 | 2026-09-15 |
| Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors Indocyanine Green (ICG) - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Margin Assessment | Phase 2 | Recruiting | Medical University of South Carolina | 30 | 2026-05-04 | 2026-07-07 |
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities EGCG and Quinine Sulfate Vaginal Suppository, Placebo - High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion | Phase 2 | Recruiting | Amplexd Therapeutics, Inc. | 45 | 2026-04-30 | 2026-05-14 |
| Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV Nonavalent HPV vaccine (9vHPV) - HPV, High-risk HPV (Any Strain) | Phase 2 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | 80 | 2026-02-01 | 2026-02-11 |
| Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV - Brain Metastases, Adult, Brain Tumor - Metastatic | Phase 2 | Recruiting | Ayal A. Aizer, MD | 60 | 2025-12-30 | 2026-09-08 |
| Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL NWRD08 administered by electroporation, Placebo administered by electroporation - High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Recruiting | Newish Biotech (Wuxi) Co., Ltd. | 150 | 2025-11-11 | 2026-02-17 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Aminolevulinic acid hydrochloride 10% topical gel with Red Light - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | The Center for Clinical and Cosmetic Research | 20 | 2024-08-14 | 2024-08-29 |
| Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial 85%TCA topical application, 3% acetic acid - Cervical Intraepithelial Neoplasia, Trichloroacetic Acid | Phase 2 | Unknown | Department of Medical Services Ministry of Public Health of Thailand | 44 | 2024-08-01 | 2024-11-14 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer | Phase 1 / Phase 2 | Completed | University College, London | 21 | 2024-05-15 | 2025-01-10 |
| B7-H3 NIR Imaging for Osteosarcoma Surgery a targeted probe B7H3-IRDye800CW - Osteosarcoma, Resection Margins | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 32 | 2024-01-01 | 2025-01-16 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Aminolevulinic Acid 20% Topical Solution with Blue Light - Facial Cutaneous Squamous Cell Carcinoma in Situ | Phase 2 | Completed | The Center for Clinical and Cosmetic Research | 32 | 2023-08-08 | 2025-02-12 |
| 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream - Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ | Phase 2 / Phase 3 | Recruiting | Boston University | 200 | 2022-10-15 | 2025-11-28 |
| A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC STP705, Placebo Saline - Squamous Cell Carcinoma in Situ | Phase 2 | Completed | Sirnaomics | 44 | 2021-05-18 | 2024-03-18 |
| Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL PVX-2, Placebo - ASC-US, ASC-H | Phase 2 | Terminated | PapiVax Biotech, Inc. | 16 | 2019-05-22 | 2024-06-17 |
| VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis - Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia | Phase 2 | Completed | AIDS Malignancy Consortium | 44 | 2018-09-21 | 2026-07-08 |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 VGX-3100, CELLECTRA™ 5PSP - Anal Neoplasm | Phase 2 | Completed | Inovio Pharmaceuticals | 23 | 2018-05-15 | 2023-07-14 |
Showing 20 of 41. Sign in to see all of them.
Squamous Intraepithelial Lesions (25) · Margins of Excision (11) · Uterine Cervical Dysplasia (11) · Atypical Squamous Cells of the Cervix (8) · Papillomavirus Infections (8) · Uterine Cervical Neoplasms (4) · Anus Neoplasms (3) · Precancerous Conditions (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Squamous Cell (2) · Infections (2) · Neoplasms (2) · Skin Neoplasms (2) · Adenocarcinoma (1)
Pathological Conditions, Signs and Symptoms (41) · Neoplasms (30) · Urogenital Diseases (22) · Genital Diseases (20) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Neoplasms by Site (19) · Genital Diseases, Female (17) · Uterine Cervical Diseases (17) · Uterine Diseases (17) · Precancerous Conditions (15) · Communicable Diseases (9) · Pathologic Processes (9) · Sexually Transmitted Diseases (9)
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (2) · Aminolevulinic Acid (2) · Biopsy (2) · Cidofovir (2) · Everolimus (2) · Indocyanine Green (2) · VGX-3100 (2) · 5-aminolaevulinic acid-n-pentylester (1) · Acetic Acid (1) · Adjuvants, Pharmaceutic (1) · Antigens (1) · Bevacizumab (1) · Biological Therapy (1) · Blue Light (1) · Celecoxib (1)
AIDS Malignancy Consortium (3) · Newish Biotech (Wuxi) Co., Ltd. (2) · The Center for Clinical and Cosmetic Research (2) · Tigris Pharmaceuticals (2) · Abramson Cancer Center at Penn Medicine (1) · Amplexd Therapeutics, Inc. (1) · Associació per a la Recerca Oncologica, Spain (1) · Ayal A. Aizer, MD (1) · Boston University (1) · Brugmann University Hospital (1) · Department of Medical Services Ministry of Public Health of Thailand (1) · GlaxoSmithKline (1) · Gynecologic Oncology Group (1) · Inovio Pharmaceuticals (1) · Institut d'Investigació Biomèdica de Bellvitge (1)
United States (25) · China (5) · Belgium (4) · France (3) · Puerto Rico (3) · Canada (2) · Hong Kong (2) · Spain (2) · Thailand (2) · United Kingdom (2) · Brazil (1) · Czechia (1) · Egypt (1) · Germany (1) · Greece (1)
Joel Palefsky, MD (3) · Cynthia J Goldberg, MD (2) · Keith A Aqua, MD (2) · Mark H Einstein, MD (2) · Mark S Nestor, MD, PhD (2) · Robert Pfeffer, MD (2) · Alexander Lin, MD (1) · Allan T Sawyer, MD (1) · Ana Eduardo, MD (1) · Ayal A Aizer, MD, MHS (1) · Baju Adji (1) · Beihua Kong, MD (1) · Bilal Fawaz, MD (1) · Brenda LaTowsky, MD (1) · Brian Jiang, MD (1)
PMID 20812850, PMID 23032420, PMID 25851632, PMID 29304768, PMID 31785337, PMID 32654362, PMID 34907980, PMID 36607735, PMID 37146227, PMID 38502871, PMID 41309506
2008 (2), U01CA121947 (2), U10CA037429 (1), U10CA101165 (1), U24CA275417 (1), UM1CA121947 (1)